Carbonyl reduction of daunorubicin in rabbit liver and heart

Pharmacology and Toxicology

Volumn 80, Issue 5, 1997, Pages 240-245

  Pröpper, Dirk ^a   Maser, Edmund ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CARBONYL REDUCTASE; DAUNORUBICIN; DAUNORUBICINOL; DRUG METABOLITE; ISOENZYME; QUERCITRIN;

ANIMAL TISSUE; ARTICLE; CARDIOTOXICITY; CONTROLLED STUDY; DRUG DETERMINATION; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME HISTOCHEMISTRY; HEART; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LIVER; LIVER METABOLISM; LIVER MICROSOME; METABOLITE; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ASSAY; RABBIT;

ANIMALIA; ORYCTOLAGUS CUNICULUS;

EID: 0030978828     PISSN: 09019928     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0773.1997.tb01966.x     Document Type: Article

References (47)

1. Bachur, N. R.: Daunorubicinol, a major metabolite of daunorubicin. J. Pharmacol. Exp. Ther. 1971, 177, 573-578.
2. Benjamin, R. S., C. E. Riggs, Jr. & N. R. Bachur: Pharmacokinetics and metabolism of adriamycin in man. Clin. Pharmacol. Therap. 1973, 14, 592-600.
3. Boucek, R. J., R. D. Olson, D. E. Brenner, E. M. Ogunbunmi, M. Inui & S. Fleischer: The major metabolite of doxorubicin is a potent inhibitor of membrane-associated ion pumps. J. Biol. Chem. 1987, 262, 15851-15856.
4. Cusack, B. J., D. A. Tesnohlidek, V. L. Loseke, R. E. Vestal, D. E. Brenner & R. D. Olson: Effect of phenytoin on the pharmacokinetics of doxorubicin and doxorubicinol in the rabbit. Cancer Chemother. Pharmacol. 1988, 22, 294-298.
5. Cusack, B. J., P. S. Mushlin, L. D. Voulelis, X. Li, R. J. Boucek & R. D. Olson: Daunorubicin-induced cardiac injury in the rabbit: a role for daunorubicinol. Toxicol. Appl. Pharmacol. 1993, 118, 177-185.
6. Del Tacca, M., R. Danesi, M. Ducci, C. Bernardini & A. Romanini: Might adriamycinol contribute to adriamycin-induced toxicity. Pharmacol. Res. Com. 1985, 17, 1073-1084.
7. Demant, E. F. J. & K. Wassermann: Doxorubicin induced alterations in lipid metabolism of cultured myocardial cells. Biochem. Pharmacol. 1985, 34, 1741-1746.
8. Doroshow, J. H., G. Y. Locker, I. Ifrim & C. E. Myers: Prevention of doxorubicin cardiac toxicity in the mouse by N-acetylcysteine. J. Clin. Invest. 1981, 68, 1053-1064.
9. Doroshow, J. H.: Effect of anthracycline antibiotics on oxygen radicals formation in rat heart. Cancer Res. 1983, 43, 460-465.
10. Felsted, R. L., M. Gee & N. R. Bachur: Rat liver daunorubicin reductase, an aldo-keto reductase. J. Biol. Chem. 1974, 249, 3672-3679.
11. Felsted, R. L., D. R. Richter & N. R. Bachur: Rat liver aldehyde reductase. Biochem. Pharmacol. 1977, 26, 1117-1124.
12. Felsted, R. L. & N. R. Bachur: Mammalian carbonyl reductases. Drug Metab. Rev. 1980, 11, 1-60.
13. Felsted, R.L. & N.R. Bachur: Human liver daunorubicin reductases: In: Enzymology of carbonyl metabolism. Eds.: H. Weiner & B. Wermuth. Alan R. Liss, New York, 1982, 291-305.
14. Goodman, J. & P. Hochstein: Generation of free radicals and lipid peroxidation by redox cycling of adriamycin and daunomycin. Biochem. Biophys. Res. Com. 1977, 77, 797-803.
15. Herman, E. H., V. J. Ferrans, C. E. Myers & J. F. Van Vleet: Comparison of the effectiveness of IRCF-187 and N-acetylcysteine in preventing chronic doxorubicin cardiotoxicity in beagles. Cancer Res. 1985, 45, 276-281.
16. Huffman, D. H., R. S. Benjamin & N. R. Bachur: Daunorubicin metabolism in acute nonlymphocytic leukemia. Clin. Pharmacol. Therap. 1972, 13, 895-905.
17. Jackson, J. A., J. P. Reeves, K. H. Muntz, D. Kruk, R. A. Prough, J. T. Willerson & L. M. Buja: Evaluation of free radical effects and catecholamine alterations in adriamycin cardiotoxicity. Amer. J. Pathol. 1984, 117, 140-153.
18. Julicher, R. H. M., L. Sterrenberg, A. Bast, R. O. W. M. Riksen, J. M. Koomen & J. Noordhoek: The role of lipid peroxidation in acute doxorubicin-induced cardiotoxicity as studied in rat isolated heart. J. Pharm. Pharmacol. 1985, 38, 277-282.
19. Li, X., B. J. Cusack, R. J. J. Boucek, P. S. Mushlin, T. B. Bledsoe, D. E. Brenner & R. D. Olson: Effects of daunorubicin and its primary metabolite, daunorubicinol, on cardiac contractility and calcium loading of sarcoplasmic reticulum. FASEB J. 1991, 5, A1395 (Abstract).
20. Loveless, H., E. Arena, R. L. Felsted & N. R. Bachur: Comparative mammalian metabolism of adriamycin and daunorubicin. Cancer Res. 1978, 38, 593-596.
21. Lowry, O. H., N. J. Rosebrough, A. L. Farr & R. J. Randall: Protein measurements with the Folin phenol reagent. J. Biol. Chem. 1951, 193, 265-275.
22. Maser, E.: Xenobiotic carbonyl reduction and physiological steroid oxidoreduction - the pluripotency of several hydroxysteroid dehydrogenases. Biochem. Pharmacol. 1995, 49, 421-440.
23. Maser, E. & G. Bannenberg: 11ß-Hydroxysteroid dehydrogenase mediates reductive metabolism of xenobiotic carbonyl compounds. Biochem. Pharmacol. 1994, 47, 1805-1812.
24. Moore, L., E. J. Landon & D. A. Cooney: Inhibition of the cardiac mitochondrial calcium pump by adriamycin. Biochem. Med. 1977, 18, 131-137.
25. Mushlin, P. S., R. J. Boucek, D. E. Brenner, B. J. Cusack, S. Fleischer & R. D. Olson: Doxorubicinol: the culprit in doxorubicin cardiotoxicity?. Fed. Proc. (Abstract) 1986, 45, 195
26. Mushlin, P. S., B. J. Cusack, R. J. J. Boucek, T. Andrejuk, X. Li & R. D. Olson: Time-related increases in cardiac concentrations of doxorubicinol could interact with doxorubicin to depress myocardial contractile function. Br. J. Pharmacol. 1993, 110, 975-982.
27. Myers, C., R. Bonow, S. Palmeri, J. Jenkins, B. Corden, G. Locker, J. Doroshow & S. Epstein: A randomized controlled trial assessing the prevention of doxorubicin cardiomyopathy by N-acetylcysteine. Semin. Oncol. 1983, 10, 53-55.
28. Myers, C. E., W. P. McGuire, R. H. Liss, I. Ifrim, K. Grotzinger & R. C. Young: Adriamycin: the role of lipid peroxidation in cardiac toxicity and tumor response. Science 1977, 197, 165-167.
29. Ohara, H., Y. Miyabe, Y. Deyashiki, K. Matsuura & A. Hara: Reduction of drug ketones by dihydrodiol dehydrogenases, carbonyl reductase and aldehyde reductase of human liver. Biochem. Pharmacol. 1995, 50, 221-227.
30. Olson, R. D., D. E. Brenner, P. S. Mushlin, R. C. Boerth, K. R. Hande & R. J. J. Boucek: Doxorubicinol: a more potent cardiotoxin than doxorubicin. Proc. Am. Assoc. Cancer Res. 1985, 26, 227-231.
31. Olson, R. D., P. S. Mushlin, D. E. Brenner, S. Fleischer, B. J. Cusack, B. K. Chang & R. J. Boucek Jr.: Doxorubicin cardiotoxicity may be caused by its metabolite, doxorubicinol. Proc. Natl. Acad. Sci. USA 1988, 85, 3585-3589.
32. Olson, R. D. & P. S. Mushlin: Doxorubicin cardiotoxicity: analysis of prevailing hypotheses. FASEB J. 1990, 4, 3076-3086.
33. Paraidathathu, T., A. B. Combs & J. P. Kehrer: In vivo effects of 1,3-bis(2-chloroethyl)-1-nitrosurea and doxorubicin on the cardiac and hepatic glutathione systems. Toxicology 1985, 35, 113-124.
34. Peters, J. H., G. R. Gordon, D. Kashiwase & E. M. Acton: Tissue distribution of doxorubicin and doxorubicinol in rats receiving multiple doses of doxorubicin. Cancer Chemother. Pharmacol. 1981, 7, 65-70.
35. Porta, E. A., N. S. Joun, L. Matsumura, B. Nakasone & H. Sablan: Acute adriamycin cardiotoxicity in rats. Res. Commun. Chem. Pathol. Pharmacol. 1983, 41, 125-137.
36. Pouna, P., S. Bonoron-Adele, G. Gouverneur, L. Tariosse, P. Besse & J. Robert: Development of the model of rat isolated perfused heart for the evaluation of anthracycline cardiotoxicity and its circumvention. Brit. J. Pharmacol. 1996, 117, 1593-1599.
37. Rajagopalan, S., P. M. Politi, B. K. Sinha & C. E. Myers: Adriamycin-induced free radical formation in the perfused rat heart: implications for cardiotoxicity. Cancer Res. 1988, 48, 4766-4769.
38. Rhoden, W., P. Hasleton & N. Brooks: Anthracyclines and the heart. Brit. Heart J. 1993, 70, 499-502.
39. Robert, J.: Pharmacokinetics and metabolism of anthracyclines in man. Pathol. Biol. Paris 1987, 35, 27-30.
40. Rossini, L., E. Monti, D. Cova & F. Piccini: Determination of doxorubicin and doxorubicin-3-ol in rat heart. Arch. Toxicol. 1986, 9 (Suppl.), 474-478.
41. Smolen, A. & A. D. Anderson: Partial purification and characterization of a reduced nicotinamide adenine dinucleotide phosphate-linked aldehyde reductase from rat heart. Biochem. Pharmacol. 1976, 25, 317-323.
42. Soldan, M., K. J. Netter & E. Maser: Induction of daunorubicin carbonyl reducing enzymes by daunorubicin in sensitive and resistant pancreas carcinoma cells. Biochem. Pharmacol. 1996, 51, 117-123.
43. Takanashi, S. & N. R. Bachur: Daunorubicin metabolites in human urine. J. Pharmacol. Exp. Therap. 1975, 195, 41-49.
44. Turner, A. J. & P. E. Hick: Metabolism of daunorubicin by a barbiturate-sensitive aldehyde reductase from rat liver. Biochem. J. 1976, 159, 819-822.
45. Unverferth, D. V., R. D. Magorien, C. V. Leier & S. P. Balcerzak: Doxorubicin cardiotoxicity. Cancer Treat. Rev. 1982, 9, 149-164.
46. Unverferth, D. V., C. V. Leier, S. P. Balcerzak & R. L. Hamlin: Usefulness of a free radical scavenger in preventing doxorubicin-induced heart failure in dogs. Amer. J. Cardiol. 1985, 56, 157-161.
47. Van Vleet, J. F., V. J. Ferrans & W. E. Weirich: Cardiac disease induced by chronic Adriamycin administration in dogs and an evaluation of vitamin E and selenium ascardioprotectants. Amer. J. Pathol. 1980, 99, 13-42.